Connective tissue
growth factor (CTGF) is overexpressed in pancreatic ductal adenocarcinoma
(PDAC) and facilitates local desmoplasia, tumor progression and
metastasis in animal models.
This study
evaluated safety and initial efficacy of the anti-CTGF antibody FG-3019 in
combination with gemcitabine and erlotinib in patients with previously
untreated Stage III or Stage IV PDAC.
Eight escalating
FG-3019 doses/regimens ranging from 3 to 45 mg/kg Q2W and 17.5 and 22.5 mg/kg
QW were evaluated. Toxicity, tumor response by CA19.9 and CT scan RECIST
criteria, progression-free and overall survival were assessed.
No comments:
Post a Comment